المؤلفون: Peri M, Fazio N

المصدر: Lung Cancer: Targets and Therapy, Vol Volume 11, Pp 41-52 (2020)

مصطلحات موضوعية: lung net, typical carcinoid, atypical carcinoid, everolimus, mammalian target of rapamycin (mtor) inhibitor, targeted agents, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://www.dovepress.com/clinical-evaluation-of-everolimus-in-the-treatment-of-neuroendocrine-t-peer-reviewed-article-LCTTTest; https://doaj.org/toc/1179-2728Test

الوصول الحر: https://doaj.org/article/8a5ffe49e6b4458080b83ed597982c1bTest

المؤلفون: Meng Lingzhan, Liu Zhenwen, Zhu Zhenyu

المصدر: Qiguan Yizhi, Vol 11, Iss 5, Pp 646-650 (2020)

مصطلحات موضوعية: de novo malignancy, immunosuppression, liver transplantation, mammalian target of rapamycin (mtor) inhibitor, lcsh:R, virus infection, lcsh:Medicine, smoking-related malignancy, hepatocellular carcinoma, precancerous lesion

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doajarticles::65418842c6089b35f7a546fb4cfb2019Test
http://www.organtranspl.com/browse/detail/qkid/46/id/1082.htmlTest

المؤلفون: A. Popov M., O. Karyakin B., A. Kaprin D., А. Попов М., О. Карякин Б., А. Каприн Д.

المصدر: Research and Practical Medicine Journal; Том 2, № 4 (2015); 128-131 ; Исследования и практика в медицине; Том 2, № 4 (2015); 128-131 ; 2410-1893 ; 2409-2231 ; 10.17709/2409-2231-2015-4

مصطلحات موضوعية: renal cell carcinoma, medical treatment, tyrosine kinase inhibitor, mammalian target of rapamycin (mTOR) inhibitor, почечно-клеточный рак, лекарственная терапия рака почки, тирозинкиназный ингибитор, mTOR ингибитор

وصف الملف: application/pdf

العلاقة: https://www.rpmj.ru/rpmj/article/view/112/119Test; Hass N. B., Manola J., Uzzo R. G., et al. Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial. J Clin Oncol. 2015; 33 Suppl 7; abstr 403.; Porta C., Procopio G., Cartenì G., Sabbatini R., Bearz A., Chiappino I., Ruggeri E. M., Re G. L., Ricotta R., Zustovich F., Landi L., Calcagno A., Imarisio I., Verzoni E., Rizzo M., Paglino C., Guadalupi V., Bajetta E. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma: an Italian multicenter retrospective analysis of 189 patient cases. BJU Int 2011; 108 (8): E250–257.; Eichelberg C., Vervenne W. L., De Santis M., Fischer von Weikersthal L., Goebell P. J., Lerchenmüller C., Zimmermann U., Bos M. M., Freier W., Schirrmacher-Memmel S., Staehler M., Pahernik S., Los M., Schenck M., Flörcken A., van Arkel C., Hauswald K., Indorf M., Gottstein D., Michel M. S. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinibsorafenib in the Treatment of Metastatic Renal Cell Cancer. Eur Urol 2015; 68 (5): 837–847.; Motzer R. J., Barrios C. H., Kim T. M., Falcon S., Cosgriff T., Harker W. G., Srimuninnimit V., Pittman K., Sabbatini R., Rha S. Y., Flaig T. W., Page R., Bavbek S., Beck J. T., Patel P., Cheung F. Y., Yadav S., Schiff E. M., Wang X., Niolat J., Sellami D., Anak O., Knox J. J. Phase II randomized trial comparing sequential firstline everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014; 32 (25): 2765–2772.; Bracarda S., Iacovelli R., Boni L., Rizzo M., Derosa L., Rossi M., Galli L., Procopio G., Sisani M., Longo F., Santoni M., Morelli F., Di Lorenzo G., Altavilla A., Porta C., Camerini A., Escudier B.; Rainbow Group. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: The RAINBOW analysis. Ann Oncol. 2015; 26 (10): 2107–13.; Lee J. L., Kim M. K., Park I., Ahn J. H., Lee D. H., Ryoo H. M., Song C., Hong B., Hong J. H., Ahn H. Randomized phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial. Ann of Oncol 2015; 26 (11): 2300–2305.; Ljungberg B., Bensalah K., Canfield S., Dabestani S., Hofmann F., Hora M., Kuczyk M. A., Lam T., Marconi L., Merseburger A. S., Mulders P., Powles T., Staehler M., Volpe A., Bex A. Guidelines on renal cell carcinoma. Eur Urol. 2015; 67 (5): 913–924.; Davis I. D., Long A., Martin A., et al. EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (aRCC) (ANZUP trial 0901). J Clin Oncol. 2014; 32 Suppl 4 (abstr 438).; Motzer R. J., Escudier B., Oudard S., Hutson T. E., Porta C., Bracarda S., Grünwald V., Thompson J. A., Figlin R. A., Hollaender N., Urbanowitz G., Berg W. J., Kay A., Lebwohl D., Ravaud A; RECORD‑1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008; 372 (9637): 449–456.; Motzer R. J., Alyasova A., Ye D., et al. Phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD‑4). ASCO. 2015; abstr. 4518; Alekseev B., Yang L., Alyasova A., et al. RECORD‑4 Multicenter phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma: pooled anti-VEGF cohort subanalysis. ESMO. 2015; abstr. 2620; Thiery-Vuillemin A., Theodore C., Jacobasch L., Schmitz J., Papandreou C., Guillot A., Emmanouilides C., Slimane K., Kelkouli N., Kim S., Nguyen Tan Hon T. Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study. Clin Genitourin Cancer. 2015; 13 (3): 231–238.; Tsimafeyeu I., Snegovoy A., Varlamov S., Safina S., Varlamov I., Gurina L., Manzuk L. Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T. Targ Oncol. 2015; 10 (3): 423–427.; Hutson T. E., Escudier B., Esteban E., Bjarnason G. A., Lim H. Y., Pittman K. B., Senico P., Niethammer A., Lu D. R., Hariharan S., Motzer R. J. Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol. 2014; 32 (8): 760–767.; Iacovelli R., Santoni M., Verzoni E., Grassi P., Testa I., de Braud F., Cascinu S., Procopio G. Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature data. Clin Genitourin Cancer. 2015; 13 (2): 137–141.; Escudier B., Michaelson M. D., Motzer R. J., Hutson T. E., Clark J. I., Lim H. Y., Porfiri E., Zalewski P., Kannourakis G., Staehler M., Tarazi J., Rosbrook B., Cisar L., Hariharan S., Kim S., Rini B. I. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. BJC 2014; 110 (12): 2821–2828.; Bergmann L., Kube U., Doehn C., Steiner T., Goebell P. J., Kindler M., Herrmann E., Janssen J., Weikert S., Scheffler M. T., Schmitz J., Albrecht M., Staehler M. Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: final results of a noninterventional study. BMC Cancer 2015; 15: 303.; Armstrong A., et al. Presented at: 2015 ASCO annual meeting; 29 May‑2 June 2015; Chicago, IL. Abstract 4507; Ravaud A., Oudard S., De Fromont M., Chevreau C., Gravis G., Zanetta S., Theodore C., Jimenez M., Sevin E., Laguerre B., Rolland F., Ouali M., Culine S., Escudier B. First-line treatment with sunitinib for type I and type II locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG). Ann of Oncol. 2015; 26 (6): 1123–1128.; Motzer R. J., Escudier B., McDermott D. F., George S., Hammers H. J., Srinivas S., Tykodi S. S., Sosman J. A., Procopio G., Plimack E. R., Castellano D., Choueiri T. K., Gurney H., Donskov F., Bono P., Wagstaff J., Gauler T. C., Ueda T., Tomita Y., Schutz F. A., Kollmannsberger C., Larkin J., Ravaud A., Simon J. S., Xu L. A., Waxman I. M., Sharma P.; CheckMate 025 Investigators. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373 (19): 1803–1813.; Choueiri T. K., Figueroa D. J., Fay A. P., Signoretti S., Liu Y., Gagnon R., Deen K., Carpenter C., Benson P., Ho T. H., Pandite L., de Souza P., Powles T., Motzer R. J. Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial. Clin Cancer Res. 2015; 21 (5): 1071–1077.; https://www.rpmj.ru/rpmj/article/view/112Test

الإتاحة: https://doi.org/10.17709/2409-2231-2015-2-4-128-131Test
https://doi.org/10.17709/2409-2231-2015-4Test
https://www.rpmj.ru/rpmj/article/view/112Test

المؤلفون: А. Array Попов, А. Array Каприн, О. Array Карякин

المصدر: Issledovaniâ i Praktika v Medicine, Vol 2, Iss 4, Pp 128-131 (2016)

مصطلحات موضوعية: Oncology, medicine.medical_specialty, renal cell carcinoma, Medical treatment, business.industry, General Arts and Humanities, mammalian target of rapamycin (mtor) inhibitor, medicine.disease, Clinical Practice, 03 medical and health sciences, Drug treatment, 0302 clinical medicine, tyrosine kinase inhibitor, Renal cell carcinoma, 030220 oncology & carcinogenesis, Internal medicine, Immunology, medicine, Medicine, 030212 general & internal medicine, medical treatment, business, Kidney cancer

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc203a7795d6d1e8303798360f23894cTest
https://www.rpmj.ru/rpmj/article/view/112Test

المؤلفون: Wahid, Sharjil, Chiang, Ping Chia, Luo, Hao Lun, Huang, Shun-Chen, Tsai, Eing-Mei, Chiang, Po Hui

المصدر: Medicine

مصطلحات موضوعية: Adult, lymphangioleiomyomatosis, Antineoplastic Agents, tuberous sclerosis, Middle Aged, bacterial infections and mycoses, everolimus, angiomyolipoma, Pelvis, immune system diseases, mammalian target of rapamycin (mTOR) inhibitor, hemic and lymphatic diseases, Humans, lipids (amino acids, peptides, and proteins), Female, Clinical Case Report, Research Article, Pelvic Neoplasms

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=pmid________::1e1afa4be9074b0d7ca20dbacf2dcc7bTest
http://europepmc.org/articles/PMC5348141Test

المؤلفون: Kengo Takeuchi, Yoshinobu Maeda, Katsuji Shinagawa, Takanori Teshima, Hisakazu Nishimori, Eisei Kondo, Takehiro Tanaka, Yoshiko Yamasuji, Ken-ichi Matsuoka, Nobuharu Fujii, Mitsune Tanimoto, Haruko Sugiyama

المصدر: Biology of Blood and Marrow Transplantation. 20(2):183-191

مصطلحات موضوعية: Adoptive cell transfer, Mammalian target of rapamycin (mTOR) inhibitor, Regulatory T cell, medicine.medical_treatment, T cell, Graft vs Host Disease, Spleen, chemical and pharmacologic phenomena, Lymphocyte Activation, T-Lymphocytes, Regulatory, Mice, medicine, Animals, PI3K/AKT/mTOR pathway, Transplantation, business.industry, TOR Serine-Threonine Kinases, Immunosuppression, Hematology, Chronic graft-versus-host disease (GVHD), medicine.disease, Adoptive Transfer, Mice, Inbred C57BL, Calcineurin, Disease Models, Animal, Graft-versus-host disease, medicine.anatomical_structure, surgical procedures, operative, Immunology, Cyclosporine, Female, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c17a5ffedef5cac1d66d7c526e2fedd9Test
https://ousar.lib.okayama-u.ac.jp/52841Test

المؤلفون: Sugiyama, Haruko, Maeda, Yoshinobu, Nishimori, Hisakazu, Yamasuji, Yoshiko, Matsuoka, Ken-ichi, Fujii, Nobuharu, Kondo, Eisei, Shinagawa, Katsuji, Tanaka, Takehiro, Takeuchi, Kengo, Teshima, Takanori, Tanimoto, Mitsune

المصدر: Biology of Blood and Marrow Transplantation

مصطلحات موضوعية: Chronic graft-versus-host disease (GVHD), Cyclosporine, Mammalian target of rapamycin (mTOR) inhibitor, Regulatory T cell

العلاقة: https://ousar.lib.okayama-u.ac.jp/files/public/5/52841/20160528115339538824/BiologyBloodMarrowTransplantation_20_2_183-191.pdfTest; https://ousar.lib.okayama-u.ac.jp/52841Test

الإتاحة: https://doi.org/10.1016/j.bbmt.2013.11.018Test
https://ousar.lib.okayama-u.ac.jp/files/public/5/52841/20160528115339538824/BiologyBloodMarrowTransplantation_20_2_183-191.pdfTest
https://ousar.lib.okayama-u.ac.jp/52841Test

المؤلفون: Katharina Kleinschmidt, Carlotta Biagi, Riccardo Masetti, Andrea Pession

المساهمون: Masetti R, Kleinschmidt K, Biagi C, Pession A

المصدر: Recent Patents on Anti-Cancer Drug Discovery. 6:354-366

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, Mammalian target of rapamycin (mTOR) inhibitor, medicine.drug_class, Farnesyltransferase inhibitors, FMS-like tyrosin kinase 3 (FLT3) inhibitor, Disease, Monoclonal antibody, Models, Biological, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Drug Discovery, medicine, Animals, Humans, Pharmacology (medical), Child, Protein Kinase Inhibitors, Heterogeneous group, business.industry, Therapies, Investigational, Childhood Acute Myeloid Leukemia, Pediatric acute myeloid leukemia, pediatric acute myeloid leukemia, Myeloid leukemia, Drugs, Investigational, General Medicine, Preclinical data, Clinical trial, Leukemia, Myeloid, Acute, DNA methyltransferase (DNMT) inhibitors and histone deacetylase (HDAC) inhibitor, Immunology, business

وصف الملف: STAMPA

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd4dd52d302094515d1dab4347230005Test
https://doi.org/10.2174/157489211796957775Test

المؤلفون: Woo-Jeong Lee, Sharada Kolekar, Christina M. Buchanan, Peter R. Shepherd, Stephen M. F. Jamieson, Jack U. Flanagan, Jackie D. Kendall, William A. Denny, Ripudaman Singh, James M. J. Dickson, Bruce C. Baguley, Gordon W. Rewcastle

المصدر: Biochemical Journal

مصطلحات موضوعية: PTEN, phosphatase and tensin homologue deleted on chromosome 10, PKB, protein kinase B, medicine.medical_treatment, TGI, tumour growth inhibition, BID, twice daily dosing, p110α E545K mutation, mTOR, mammalian target of rapamycin, ERK, extracellular-signal-regulated kinase, Biochemistry, Mice, Tumor Cells, Cultured, medicine, Animals, Humans, Protein Isoforms, Tensin, PTEN, Tissue Distribution, Enzyme Inhibitors, pan-phosphoinositide 3kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor NVP-BEZ235, phosphoinositide 3-kinase α (PI3Kα), Molecular Biology, Protein kinase B, PI3K/AKT/mTOR pathway, Phosphoinositide-3 Kinase Inhibitors, Homeodomain Proteins, Mice, Knockout, Phosphoinositide 3-kinase, biology, QD, once daily dosing, Growth factor, PIK3CA, Neoplasms, Experimental, Cell Biology, phosphoinositide 4-kinase (PI4K), PIK3CA H1047R mutation, PI4K, phosphoinositide 4-kinase, Cell biology, Class Ia Phosphatidylinositol 3-Kinase, P110δ, biology.protein, Signal transduction, Proto-Oncogene Proteins c-akt, PI3K, phosphoinositide 3-kinase, Research Article, Signal Transduction

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd1a7d1444366d807c36dc5923f61ac0Test
https://doi.org/10.1042/bj20110502Test

المؤلفون: MASETTI, RICCARDO, KLEINSCHMIDT, KATHARINA, BIAGI, CARLOTTA, PESSION, ANDREA

المساهمون: Masetti R, Kleinschmidt K, Biagi C, Pession A

مصطلحات موضوعية: DNA methyltransferase (DNMT) inhibitors and histone deacetylase (HDAC) inhibitor, Farnesyltransferase inhibitors, FMS-like tyrosin kinase 3 (FLT3) inhibitor, Mammalian target of rapamycin (mTOR) inhibitor, pediatric acute myeloid leukemia

وصف الملف: STAMPA

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/21635222; info:eu-repo/semantics/altIdentifier/wos/WOS:000295410700009; volume:6; issue:3; firstpage:354; lastpage:366; numberofpages:13; journal:RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY; http://hdl.handle.net/11585/145505Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-80052325940

الإتاحة: http://hdl.handle.net/11585/145505Test